Area of research
Physiology · Psychiatry and Mental health
Research interest
Research interests include Alzheimer's disease research and treatments, Dementia and Cognitive Impairment Research, Prion Diseases and Protein Misfolding, and Cholinesterase and Neurodegenerative Diseases.
Plasma Aβ42/40 predicts progression from Aβ-amyloid negative to positive PET scans
Prevalence of frailty and its association with cognition in preclinical Alzheimer's disease: a cross-sectional analysis of baseline data from the A4 study.
Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances.
Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials
Diagnostic accuracy of plasma p-tau217/Aβ42 for Alzheimer's disease in clinical and community cohorts.
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial.
Longitudinal analysis of a dominantly inherited Alzheimer disease mutation carrier protected from dementia
Plasma proteomics for cognitive decline and dementia—A Southeast Asian cohort study
Plasma proteomics for cognitive decline and dementia-A Southeast Asian cohort study.
Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment.
Integrative multiomics reveals common endotypes across PSEN1, PSEN2, and APP mutations in familial Alzheimer’s disease
Plasma p‐tau217, NfL, GFAP diagnostic performance and biomarker profiles in Alzheimer's disease, frontotemporal dementia, and psychiatric disorders, in a prospective unselected neuropsychiatry memory clinic
Diagnostic performance of plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non-AD dementias: An international multi-center study.
Alzheimer's disease biological PET staging using plasma p217+tau.
The structural foundations of anti-amyloid-β immunotherapies: Unravelling antibody-antigen interactions in Alzheimer's disease treatment.
Development and Validation of a Tool to Predict Onset of Mild Cognitive Impairment and Alzheimer Dementia.
Exploring epidemiological risk factors for cerebral amyloid angiopathy: Considerations for monoclonal antibody therapy in people with Alzheimer's disease.
Combining Lumipulse p-tau217 and Aβ42/40 as confirmatory tests for Aβ positivity prior to disease-modifying therapy.
Baseline habitual dietary nitrate intake and Alzheimer's Disease related neuroimaging biomarkers in the Australian Imaging, Biomarkers and Lifestyle study of ageing.
Multiomics analysis to evaluate the enrichment of extracellular vesicles from human plasma.
The moderating effect of dietary patterns on the association of depression and anxiety with cognitive function.
Rethinking the residual approach: leveraging statistical learning to operationalize cognitive resilience in Alzheimer's disease.
Halting the Progression of Alzheimer's Disease: Is the Goal in Sight?
The role of diet in moderating the relationship between symptoms of depression and brain amyloid load.
Developing and validating a prediction tool for cerebral amyloid angiopathy neuropathological severity.
Predicting amyloid beta accumulation in cognitively unimpaired older adults: Cognitive assessments provide no additional utility beyond demographic and genetic factors.
The relationship of soluble tau species with Alzheimer's disease amyloid plaque removal and tau pathology
Multivariate models using NULISAseq and plasma p-tau217 for staging Alzheimer's disease.
Predicting severity of cerebral amyloid angiopathy neuropathology: A modeling approach using NACC and ROSMAP data.